CA
NZ
UK
AU
IND
US
Matinas BioPharma built its reputation on a lipid nanocrystal (LNC) delivery platform and its lead candidate MAT2203, an oral formulation of the antifungal amphotericin B aimed at serious invasive fungal infections. On July 13, 2026, the company changed course dramatically. It signed a definitive …
Eagle Pharmaceuticals historically built its portfolio around injectable and specialty hospital products, including established franchises in oncology support and critical-care medicines, alongside efforts to broaden its pipeline. The company's trajectory changed sharply in 2024, when it disclosed that it had fallen behind on required …
YourWay Cannabis Brands describes itself as a company that, through subsidiaries, manufactures, distributes and sells cannabis in the U.S. recreational and medicinal markets. It is a Canadian-incorporated entity, tied to Vancouver, British Columbia, with a U.S. operational presence associated with Phoenix, Arizona, and its …
Outset Medical is a medical-technology company built around the Tablo Hemodialysis System, a compact console that integrates water purification, on-demand dialysate production, and connected software. The design targets both acute-care settings and, increasingly, the home, where Outset hopes to expand access to dialysis. The …
Mosaic ImmunoEngineering, based in Huntington Beach, California, is a development-stage biotechnology firm founded in 2020 that focuses on advancing immunotherapies for cancer. Its scientific heritage is rooted in plant-virus immunotherapy, and the ticker CPMV nods to cowpea mosaic virus, a plant virus studied as …
Limitless X Holdings is a diversified consumer packaged goods company focused on the nutrition, wellness and beauty sectors. Its model combines product development with direct-response advertising,Digital Marketingservices and direct-to-consumer e-commerce. Recent developments describe an effort to broaden the platform and stabilise the business: the …
Aldeyra Therapeutics is a clinical-stage biotechnology company built around reactive aldehyde species (RASP) modulation, an anti-inflammatory approach. Its lead candidate, reproxalap, is a topical treatment aimed at the signs and symptoms of dry eye disease, a large and competitive ophthalmology market. The pivotal moment …
Exicure was founded on spherical nucleic acid (SNA) technology, developing gene-regulating therapies. That platform is no longer the story. Regulatory data now describe a company that "does not have significant operations" in its former sense, having pivoted after acquiring GPCR Therapeutics USA. The centerpiece …
Instil Bio originally built its identity around tumor-infiltrating lymphocyte (TIL) cell therapies for cancer. After restructuring, the company shifted toward antibody-based oncologyAssetslicensed from China's ImmuneOnco. That strategy unraveled on January 6, 2026, when Instil's subsidiary, Axion Biosciences, announced it would discontinue clinical development of …
Tevogen Bio, which reports as Tevogen Inc., is developing allogeneic, off-the-shelf CD8+ cytotoxic T-cell therapies through a platform it calls ExacTcell. Its lead candidate, TVGN 489, targets high-risk COVID-19 and related indications such as long COVID, and the company has said a Phase 1 …
Please wait processing your request...